Compounds > triethylenemelamine
Page last updated: 2024-11-06

triethylenemelamine and Anemia, Hemolytic, Acquired

triethylenemelamine has been researched along with Anemia, Hemolytic, Acquired in 2 studies

Triethylenemelamine: Toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
TAYLOR, L1

Other Studies

2 other studies available for triethylenemelamine and Anemia, Hemolytic, Acquired

ArticleYear
IDIOPATHIC AUTOIMMUNE HEMOLYTIC ANEMIA. RESPONSE OF A PATIENT TO REPEATED COURSES OF ALKYLATING AGENTS.
    The American journal of medicine, 1963, Volume: 35

    Topics: Adrenal Cortex Hormones; Alkylating Agents; Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune

1963
Pipobroman (Vercyte) - a new antineoplastic drug.
    The Medical letter on drugs and therapeutics, 1967, Apr-07, Volume: 9, Issue:7

    Topics: Anemia, Hemolytic; Antineoplastic Agents; Bone Marrow; Busulfan; Chlorambucil; Gastrointestinal Hemo

1967